

Ralph Wäsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2784156/publications.pdf>

Version: 2024-02-01

102
papers

3,374
citations

201385

27
h-index

155451

55
g-index

105
all docs

105
docs citations

105
times ranked

4859
citing authors

#	ARTICLE	IF	CITATIONS
1	Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1045-1055.	1.2	7
2	Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 55.	1.7	12
3	Proteasome inhibition: the dawn of novel therapies in multiple myeloma. <i>Haematologica</i> , 2022, 107, 1018-1019.	1.7	2
4	A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin. <i>Leukemia and Lymphoma</i> , 2022, 63, 2260-2262.	0.6	1
5	Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. <i>Haematologica</i> , 2021, 106, 875-880.	1.7	14
6	Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 110-120.	1.3	8
7	Ruxolitinib+“ECP combination treatment for refractory severe chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 909-916.	1.3	32
8	Interdisciplinary approach to multiple myeloma –“ time to diagnosis and warning signs. <i>Leukemia and Lymphoma</i> , 2021, 62, 891-898.	0.6	4
9	Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation. <i>Journal of Geriatric Oncology</i> , 2021, 12, 521-530.	0.5	12
10	Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 841-852.	1.3	12
11	Two cases of carfilzomib+“induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. <i>BMC Nephrology</i> , 2021, 22, 32.	0.8	14
12	Case Report: Refusal of an Veno-Arterial Extracorporeal Membrane Oxygenation Due to Malignant Disease? –“ An Extremely Rare Form of Cardiac Involvement in Acute Myeloid Leukemia. <i>Frontiers in Medicine</i> , 2021, 8, 584507.	1.2	1
13	Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures. <i>BMC Cancer</i> , 2021, 21, 173.	1.1	3
14	Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab. <i>Annals of Hematology</i> , 2021, 100, 1637-1640.	0.8	1
15	A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT. <i>Annals of Hematology</i> , 2021, 100, 2095-2103.	0.8	2
16	Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis. <i>Annals of Hematology</i> , 2021, 100, 2339-2350.	0.8	16
17	In search of the optimal proteasome inhibitor. How, when and for whom?. <i>Haematologica</i> , 2021, 106, 2539-2541.	1.7	0
18	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	1.7	27

#	ARTICLE	IF	CITATIONS
19	Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. <i>Cancer</i> , 2021, 127, 3422-3436.	2.0	9
20	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. <i>Cancer</i> , 2021, 127, 3413-3421.	2.0	4
21	Novel immunotherapies in multiple myeloma – chances and challenges. <i>Haematologica</i> , 2021, 106, 2555-2565.	1.7	21
22	Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 708231.	1.3	7
23	Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. <i>Cancers</i> , 2021, 13, 4320.	1.7	11
24	Geriatric assessments and frailty scores in multiple myeloma patients. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 648-657.	1.1	16
25	The impact of pulmonary function in patients undergoing autologous stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 4327-4337.	2.5	9
26	Targeting mitotic exit in solid tumors. <i>American Journal of Cancer Research</i> , 2021, 11, 3698-3710.	1.4	0
27	First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL). <i>Blood</i> , 2021, 138, 362-362.	0.6	12
28	Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient. <i>Haematologica</i> , 2020, 105, e138-e140.	1.7	5
29	Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 1154-1157.	3.3	12
30	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 257-270.	0.8	63
31	Time from first symptom onset to the final diagnosis of multiple myeloma (MM) – possible risks and future solutions: retrospective and prospective – Deutsche Studiengruppe MM (DSMM) and – European Myeloma Network (EMN) analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 875-886.	0.6	12
32	Dapsone-Induced Hemolytic Anemia in Multiple Myeloma: Case Report of Various Differential Diagnoses. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e821-e825.	0.2	2
33	Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. <i>Haematologica</i> , 2020, 105, 2872-2878.	1.7	40
34	Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patients. <i>Cancer</i> , 2020, 126, 3504-3515.	2.0	18
35	Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. <i>Haematologica</i> , 2020, 105, 1183-1188.	1.7	46
36	Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment. <i>Haematologica</i> , 2020, 105, 859-861.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma. <i>Haematologica</i> , 2020, 105, e523.	1.7	10
38	Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial. <i>Blood</i> , 2020, 136, 9-10.	0.6	1
39	GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 199-206.	0.7	1
40	PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion. <i>Leukemia</i> , 2019, 33, 1296-1301.	3.3	5
41	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. <i>Journal of Internal Medicine</i> , 2019, 286, 63-74.	2.7	42
42	Teaming up for CAR-T cell therapy. <i>Haematologica</i> , 2019, 104, 2335-2336.	1.7	7
43	Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?. <i>Haematologica</i> , 2019, 104, 2128-2131.	1.7	3
44	APC/CCdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 369-380.	2.4	5
45	Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. <i>Haematologica</i> , 2019, 104, 370-379.	1.7	53
46	Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit) <i>TJ ETQq0 0 0 rgBT7/Overload 10 Tf 50</i>		
47	Current developments in immunotherapy in the treatment of multiple myeloma. <i>Cancer</i> , 2018, 124, 2075-2085.	2.0	49
48	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
49	Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. <i>Blood</i> , 2018, 131, 1464-1475.	0.6	57
50	Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials. <i>Leukemia and Lymphoma</i> , 2018, 59, 2692-2699.	0.6	19
51	Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule. <i>Leukemia and Lymphoma</i> , 2018, 59, 1722-1725.	0.6	4
52	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	1.7	110
53	Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. <i>Haematologica</i> , 2018, 103, 755-758.	1.7	6
54	Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2277-2284.	2.0	19

#	ARTICLE	IF	CITATIONS
55	Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018, 103, 1422-1432.	1.7	70
56	Carfilzomib. <i>Recent Results in Cancer Research</i> , 2018, 212, 265-283.	1.8	2
57	Pomalidomide. <i>Recent Results in Cancer Research</i> , 2018, 212, 169-185.	1.8	6
58	Ruxolitinib. <i>Recent Results in Cancer Research</i> , 2018, 212, 119-132.	1.8	66
59	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	3.3	83
60	Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8019-8019.	0.8	8
61	Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. <i>Leukemia and Lymphoma</i> , 2017, 58, 1849-1858.	0.6	13
62	A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. <i>Haematologica</i> , 2017, 102, 910-921.	1.7	187
63	The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. <i>European Journal of Haematology</i> , 2017, 99, 449-458.	1.1	6
64	<scp>CXCL</scp>12 and <scp>CXCR</scp>7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 179, 36-49.	1.2	63
65	Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML <i>in vitro</i> and prolongs survival <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 21153-21166.	0.8	15
66	Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?. <i>Haematologica</i> , 2016, 101, 1276-1278.	1.7	10
67	Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. <i>Haematologica</i> , 2016, 101, 1110-1119.	1.7	145
68	Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ≥60 years with advanced AML/MDS. <i>Leukemia</i> , 2016, 30, 2426-2429.	3.3	7
69	The Use of SNAP Labeling to Study Cell Cycle Oscillatory Proteins. <i>Methods in Molecular Biology</i> , 2016, 1342, 201-208.	0.4	0
70	The role of APC/CCdh1 in replication stress and origin of genomic instability. <i>Oncogene</i> , 2016, 35, 3062-3070.	2.6	29
71	Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation. <i>Blood</i> , 2016, 128, 2247-2247.	0.6	3
72	Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 48220-48230.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis. <i>Blood</i> , 2016, 128, 5979-5979.	0.6	0
74	Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. <i>Leukemia Research</i> , 2015, 39, 462-470.	0.4	14
75	Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. <i>Leukemia</i> , 2015, 29, 2062-2068.	3.3	455
76	Trained clinical nurse specialists proficiently obtain bone marrow aspirates and trephine biopsies in a nearly painless procedure—a prospective evaluation study. <i>Annals of Hematology</i> , 2015, 94, 1577-1584.	0.8	6
77	Up-regulation of <i>RUNX2</i> in acute myeloid leukemia in a patient with an inherent <i>RUNX2</i> haploinsufficiency and cleidocranial dysplasia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1930-1932.	0.6	12
78	Pomalidomide. <i>Recent Results in Cancer Research</i> , 2014, 201, 359-372.	1.8	11
79	Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 541-551.	0.2	72
80	Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 1098-1103.	1.3	20
81	BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy. <i>Haematologica</i> , 2013, 98, 1886-1895.	1.7	21
82	The 3' Untranslated Region of the Cyclin B mRNA Is Not Sufficient to Enhance the Synthesis of Cyclin B during a Mitotic Block in Human Cells. <i>PLoS ONE</i> , 2013, 8, e74379.	1.1	6
83	Monitoring APC/C activity in the presence of chromosomal misalignment in unperturbed cell populations. <i>Cell Cycle</i> , 2012, 11, 310-321.	1.3	16
84	Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations. <i>Journal of Visualized Experiments</i> , 2012, , e4239.	0.2	1
85	Aggressive plasmablastic lymphoproliferation complicated by hemophagocytic syndrome 12 years after heart transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 1845-1848.	0.6	3
86	Radiation-Free Allogeneic Conditioning with Fludarabine, Carmustine, and Thiotepa for Acute Lymphoblastic Leukemia and Other Hematologic Malignancies Necessitating Enhanced Central Nervous System Activity. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1430-1437.	2.0	15
87	Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. <i>Annals of Hematology</i> , 2012, 91, 287-289.	0.8	19
88	Cell cycle control in acute myeloid leukemia. <i>American Journal of Cancer Research</i> , 2012, 2, 508-28.	1.4	29
89	Targeting mitotic exit for cancer treatment. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 785-788.	1.5	6
90	Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM comorbidity score. <i>Blood Cancer Journal</i> , 2011, 1, e35-e35.	2.8	96

#	ARTICLE	IF	CITATIONS
91	The emerging role of APC/CCdh1 in controlling differentiation, genomic stability and tumor suppression. <i>Oncogene</i> , 2010, 29, 1-10.	2.6	107
92	Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 967-975.	2.0	42
93	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010, 51, 1424-1443.	0.6	49
94	BL_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1). <i>Recent Results in Cancer Research</i> , 2010, 184, 215-218.	1.8	23
95	Strong inducible knockdown of APC/C ^{Cdc20} does not cause mitotic arrest in human somatic cells. <i>Cell Cycle</i> , 2009, 8, 643-646.	1.3	25
96	A Novel GVHD-Prophylaxis with Low-Dose Alemtuzumab in Allogeneic Sibling or Unrelated Donor Hematopoietic Cell Transplantation: The Feasibility of Deescalation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1563-1570.	2.0	40
97	The ubiquitin ligase APCdh1 is required to maintain genome integrity in primary human cells. <i>Oncogene</i> , 2008, 27, 907-917.	2.6	105
98	Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. <i>Oncogene</i> , 2005, 24, 1-10.	2.6	119
99	APC-dependent proteolysis of the mitotic cyclin Clb2 is essential for mitotic exit. <i>Nature</i> , 2002, 418, 556-562.	13.7	212
100	Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation. <i>Annals of Hematology</i> , 2001, 80, 201-208.	0.8	16
101	Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	1
102	The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	10